Clinical

Articles

The combination demonstrated encouraging clinical activity in patients with both clear cell and non–clear cell renal cell carcinoma.  

Combo of cabozantinib plus atezolizumab active across kidney cancer subtypes

Videos

Michael S. Cookson, MD, previews the 2021 AUA Annual Meeting, with a focus on prostate, bladder, and kidney cancer. His in-depth analysis covers the plenary sessions, late-breaking abstracts, and other abstracts of interest.

2021 AUA Annual Meeting Preview: Prostate, Bladder, and Kidney Cancer

 is an associate professor of medicine in the Division of Hematology/Oncology, Department of Internal Medicine at Mayo Clinic, Phoenix, Arizona.

Patients may require specific diagnostic, surveillance, and therapeutic management.

Recognizing hereditary syndromes in renal cell carcinoma

The FDA is scheduled to decide on the application for adjuvant pembrolizumab in renal cell carcinoma on or before December 10, 2021.

Adjuvant pembrolizumab data published in NEJM as FDA weighs kidney cancer approval 

Ventana MMR RxDx Panel is a qualitative immunohistochemistry test that assesses a panel of MMR proteins to help guide clinicians in their  treatment decisions. 

FDA approves dostarlimab companion diagnostic for use across dMMR solid tumors 

The approval provides urologists with another tool for the treatment of patients with genitourinary cancers and underscores the rapidly growing significance of genetic testing in the field of urology.

FDA grants tumor-agnostic approval to immunotherapy dostarlimab

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma.

Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma

The FDA has approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma.

FDA approves belzutifan for VHL-associated kidney cancer

The FDA has approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced renal cell carcinoma.

FDA approves frontline pembrolizumab plus lenvatinib for kidney cancer

Inhibiting the HDL cholesterol receptor SCARB1 can kill and stop the proliferation of clear cell renal cell carcinoma cells.